CADTH Canadian Drug Expert Committee recommendation: Ozenoxacin 1% cream (Ozanex -- Ferrer Internacional, S.A.) indication: the topical treatment of impetigo in patients aged two months and older
The CADTH Canadian Drug Expert Committee (CDEC) recommends that ozenoxacin not be reimbursed for the treatment of impetigo
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, October 2018
|
Edition: | Version: Final |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that ozenoxacin not be reimbursed for the treatment of impetigo |
---|---|
Physical Description: | 1 PDF file (7 pages) |